Secondaries announced 3.18.2015
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Esperion Therapeutics Symbol: ESPR Price: Last trade $99.60 Trade Date: 3/19 Shares: 1.5 million Underwriter(s) Credit Suisse, RBC Capital Markets, UBS[…]